Study on Using CAIX PET/CT Scans for Detecting Remaining or Returning Kidney Cancer After Treatment

Sponsor: Massachusetts General Hospital

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT07077083

Provider View

This clinical trial is exploring whether a special PET scan using 89Zr-Girentuximab can help identify kidney cancer that remains or returns after treatment. The study will also compare scan results before and after standard treatment.

Patient Parameters

Program Overview

The purpose of this study is to find out if a PET scan with 89Zr-Girentuximab can detect clear cell renal cell carcinoma (ccRCC) that might be left behind or has come back after treatment. The study will also look at differences in scan results before and after standard treatment. Participants in one group will receive the study drug and have a PET scan 3-7 days later. Participants in another group will have the same process, but will also undergo their usual cryoablation treatment after the first PET scan, followed by a second PET scan within 3 days of the treatment.

Eligibility Criteria

Inclusion Criteria

  • Must provide written consent to participate.
  • Must be 18 years or older.
  • Must understand the study and be willing to follow all study requirements.
  • Must have signs of kidney cancer that might be left after treatment or has come back, confirmed by imaging or biopsy within the last 90 days.
  • Women who can become pregnant must have a negative pregnancy test before receiving the study drug.
  • Women who cannot become pregnant must show proof, such as being post-menopausal or having had certain surgeries.
  • All participants must agree to use two forms of birth control until at least 42 days after receiving the study drug.

Exclusion Criteria

  • Kidney mass known to be from another type of cancer.
  • Active cancer other than kidney cancer that needs treatment during the study.
  • Planned cancer treatments between receiving the study drug and imaging.
  • Previous use of certain radioactive substances too close to the study drug administration.
  • Serious non-cancerous diseases that might interfere with the study or participant safety.
  • Mental impairment affecting the ability to consent or follow study requirements.
  • Women who are pregnant or breastfeeding.
  • Known allergy to the study drug or its components.
  • Poor kidney function with specific test results.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.